Pfizer and BioNTech announced that the Covid-19 vaccine they are developing together is on target to be submitted for regulatory approval as early as October, as additional results from the early-stage analysis were published.
Pfizer-BioNTech COVID-19 Vaccine Could Be Approved By October – Insiderfolks, US pharmaceutical giant Pfizer and German biotech firm BioNTech published protection and immunogenicity results from the Phase 1 trial of their second and lead mRNA-based coronavirus vaccine candidate.
Pfizer and BioNTech announced that the Covid-19 vaccine they are designing together is on target to be submitted for regulatory approval as early as October.
The companies indicated that the vaccination was well absorbed with mild to moderate fever in less than 20% of participants. The firms are starting to evaluate results from phase 1 studies in the United States and Germany.
The BNT162b2 vaccine appeared to have a strong immune reaction, but less adverse effects than the other BNT162b1 vaccine. Systemic events following administration of BNT162b2 were milder than those of BNT162b1 recorded in the publication.
“The entirety of clinical and pre-clinical evidence told Pfizer and BioNTech of the decision to pick BNT162b2 as the lead candidate for advancement in pivotal trials.
We are pleased to share our discoveries with the science community while we continue to strive to produce a secure and efficient vaccine to fight this deadly virus, “said Kathrin U Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Growth, Pfizer.
“We are particularly pleased to have these early results showing the promising protection and immunogenicity profile of our vaccine candidate from the US trial and look forward to sharing T cell immune response results from the German trial in the near future.”
Confirming their October target, first announced last month, will render the vaccine one of the fastest-moving vaccines in the world.
Some experts predict that the vaccination will be licensed for use by November in the U.S., a development that could offer President Donald Trump a new foothold in the election.
Pfizer and BioNTech reached a $2 billion contract last month to provide the U.S. with an estimated 100 million doses of the vaccine.
Governments around the globe are trying to lock up stocks of still-experimental candidates in hopes of stabilizing local markets and preventing the spread of the epidemic that has claimed almost 800,000 lives worldwide.
Get Breaking news, live coverage, and Latest News from India and around the world on insiderfolks.com. Catch all the updates from www.insiderfolks.com, Subscribe to our Youtube channel for more latest news updates: http://bit.ly/2neVPFM, Like us on Facebook or follow us on Twitter and Instagram for the latest news links below.
Connect with insider folks: For the more latest in news and lifestyle visit: http://insiderfolks.com/ Facebook: https://www.facebook.com/Insiderfolks/ Twitter: https://twitter.com/InsiderFolks Instagram: https://www.instagram.com/insider_folks/